Tweet
Source: http://www.nasdaq.com/article/vical-...20120305-00208
Mar 8, 2012
Vical Says U.S. Navy Advances Dengue DNA Vaccine Using Its Vaxfectin Adjuvant
(RTTNews.com) - Vical Inc. (VICL) said the Naval Medical Research Center, or NMRC, has begun a Phase 1 human clinical trial of a tetravalent dengue DNA vaccine formulated with the company's Vaxfectin adjuvant. Vical manufactured the vaccine and the adjuvant for both the preclinical and clinical studies, and is providing regulatory and clinical expertise to NMRC for the dengue program.
Mar 8, 2012
Vical Says U.S. Navy Advances Dengue DNA Vaccine Using Its Vaxfectin Adjuvant
(RTTNews.com) - Vical Inc. (VICL) said the Naval Medical Research Center, or NMRC, has begun a Phase 1 human clinical trial of a tetravalent dengue DNA vaccine formulated with the company's Vaxfectin adjuvant. Vical manufactured the vaccine and the adjuvant for both the preclinical and clinical studies, and is providing regulatory and clinical expertise to NMRC for the dengue program.